Tobias Bopp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tobias Bopp has a total of 705 co-authors. Here are the top co-authors by number of shared publications:
Matthias Klein
Institute for Immunology, University Medical Center Mainz, Johannes Gutenberg-University Mainz, Germany
29 shared publications- Matthias Klein
Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
16 shared publications - Magdalena Huber
Institute of Systems Immunology, Philipps University of Marburg, Marburg, Germany
14 shared publications - Felix Simon Ruben Picard
Heart Center, Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, North Rhine-Westphalia, Germany
12 shared publications - Andreas Weigert
Institute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany
11 shared publications - Ari Waisman
Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz
11 shared publications
Latest Publications
- Open Access
Macrophage-mediated bystander T cell activation in varicose veins
Background: Up to one-third of all adults are affected by chronic venous insufficiency, with varicose veins being a common manifestation of the condition. It is believed that inflammation plays a central role in the progression of the disease; however, the immune cell populations and mechanisms involved remain unclear. Methods: Varicose veins were subjected to a stepwise mechanical and enzymatic dissociation, and the mononuclear cells resulting from these steps were characterized by flow cytometry. CD206-negative connective tissue macrophages and CD206-positive venous wall macrophages were sorted from five donors and subjected to transcriptomic profiling. Cytokine production by T cells in varicose veins was characterized following inhibition of intracellular protein transport. The ability of cytokines identified in macrophage transcriptomes to induce cytokine production in CD8 + and CD4 + effector and memory T cells was investigated using combinations of recombinant cytokines. Results: Varicose veins harbor CD206 neg IL-1α + S100A8/9 + macrophages in the connective tissue and pro-resolving and tissue regenerating CD206 + TIMD4 + LYVE1 + macrophages in the vein wall. T cells predominantly localize within the connective tissue, express an effector-memory T cell phenotype and produce IFN-γ in situ. Cytokines identified in the macrophage transcriptome collectively induced IFN-γ, as well as TNF-α, IL-22, and GM-CSF in effector memory T cells; in addition to IL-15 and IL-18, TNF-α and IL-10 proved to be key drivers. Conclusions: The identified macrophage-T cell cytokine axis contributes to chronic venous insufficiency pathogenesis and represents a potential therapeutic target. Abstract Figure:
Open AccessMacrophage-mediated bystander T cell activation in varicose veins
Background: Up to one-third of all adults are affected by chronic venous insufficiency, with varicose veins being a common manifestation of the condition. It is believed that inflammation plays a central role in the progression of the disease; however, the immune cell populations and mechanisms involved remain unclear. Methods: Varicose veins were subjected to a stepwise mechanical and enzymatic dissociation, and the mononuclear cells resulting from these steps were characterized by flow cytometry. CD206-negative connective tissue macrophages and CD206-positive venous wall macrophages were sorted from five donors and subjected to transcriptomic profiling. Cytokine production by T cells in varicose veins was characterized following inhibition of intracellular protein transport. The ability of cytokines identified in macrophage transcriptomes to induce cytokine production in CD8 + and CD4 + effector and memory T cells was investigated using combinations of recombinant cytokines. Results: Varicose veins harbor CD206 neg IL-1α + S100A8/9 + macrophages in the connective tissue and pro-resolving and tissue regenerating CD206 + TIMD4 + LYVE1 + macrophages in the vein wall. T cells predominantly localize within the connective tissue, express an effector-memory T cell phenotype and produce IFN-γ in situ. Cytokines identified in the macrophage transcriptome collectively induced IFN-γ, as well as TNF-α, IL-22, and GM-CSF in effector memory T cells; in addition to IL-15 and IL-18, TNF-α and IL-10 proved to be key drivers. Conclusions: The identified macrophage-T cell cytokine axis contributes to chronic venous insufficiency pathogenesis and represents a potential therapeutic target. Abstract Figure:
- Open Access
- 29 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7588
B cell CD19 is transferred between immune cells in mice and humans
When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutic monoclonal antibodies. By using mouse and human B-T cell co-cultures, we report that CD19, an assumingly exclusive B cell marker, is transferred via trogocytosis when B cells activate T cells. In a B cell-driven model of experimental autoimmune encephalomyelitis, CD19 + T cells expand and show enhanced features of activation, differentiation, and encephalitogenic potential ex vivo. Additionally, co-transfer of CD19 and functional IgM from B cells results in the gain of B cell function by T cells. In patients with chronic central nervous system (CNS) demyelination, CD19 + T cells display a pro-inflammatory phenotype and are concomitantly depleted by inebilizumab, an approved anti-CD19 antibody, which raises important considerations for the therapeutic use of monoclonal antibodies overall. Finally, we report that myeloid cells acquire CD19 and functional IgM after phagocytosis of apoptotic B cells and thereby gain functional B cell properties. These findings highlight the commonness of membrane and antigen-transfer between cells, resulting in transmission of cellular function.
- 29 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7588
Open AccessB cell CD19 is transferred between immune cells in mice and humans
When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutic monoclonal antibodies. By using mouse and human B-T cell co-cultures, we report that CD19, an assumingly exclusive B cell marker, is transferred via trogocytosis when B cells activate T cells. In a B cell-driven model of experimental autoimmune encephalomyelitis, CD19 + T cells expand and show enhanced features of activation, differentiation, and encephalitogenic potential ex vivo. Additionally, co-transfer of CD19 and functional IgM from B cells results in the gain of B cell function by T cells. In patients with chronic central nervous system (CNS) demyelination, CD19 + T cells display a pro-inflammatory phenotype and are concomitantly depleted by inebilizumab, an approved anti-CD19 antibody, which raises important considerations for the therapeutic use of monoclonal antibodies overall. Finally, we report that myeloid cells acquire CD19 and functional IgM after phagocytosis of apoptotic B cells and thereby gain functional B cell properties. These findings highlight the commonness of membrane and antigen-transfer between cells, resulting in transmission of cellular function.
- 2 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (11) , 1454-1465
Type I interferon-activated NK cells control polycythemia vera in vivo
Polycythemia vera (PV) is a clonal hematopoietic stem cell (HSC) disorder resulting in overproduction of erythrocytes. While Interferon-a (IFN-a) has shown therapeutic efficacy in PV and other myeloproliferative neoplasms (MPN), its precise mechanism of action remains poorly understood. In this study, we identify natural killer (NK) cells as primary immune effectors responsive to IFN-a treatment in PV essential for disease control in vivo. Using a transgenic mouse model of PV, we demonstrate that IFN-a induces the expansion of CD27+ NK cells in the bone marrow. In patients with PV or ET undergoing IFN-a therapy, the frequency of CD56bright NK cells is increased and correlates with the molecular response. Depletion of NK cells abrogated the therapeutic effects of IFN-a. In vitro experiments demonstrate that NK cells preferentially killed Jak2VF mutant hematopoietic stem and progenitor cells (HSPCs) in a TNF-a dependent manner and independent of IFN-g or NKG2D. Notably, PV mice depleted of NK cells or lacking type-I interferon (IFN) receptor on NK cells showed accelerated disease progression in the absence of exogenous IFN-a. This suggests that direct sensing of basal levels of type-I IFNs by NK cells is essential for attenuating disease progression, emphasizing a critical role for NK cells in immune surveillance of MPN. These findings offer new insights into type-I IFN-mediated immune modulation in MPN and highlight the potential of NK cell activation to improve therapeutic outcomes.
- 2 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (11) , 1454-1465
Type I interferon-activated NK cells control polycythemia vera in vivo
Polycythemia vera (PV) is a clonal hematopoietic stem cell (HSC) disorder resulting in overproduction of erythrocytes. While Interferon-a (IFN-a) has shown therapeutic efficacy in PV and other myeloproliferative neoplasms (MPN), its precise mechanism of action remains poorly understood. In this study, we identify natural killer (NK) cells as primary immune effectors responsive to IFN-a treatment in PV essential for disease control in vivo. Using a transgenic mouse model of PV, we demonstrate that IFN-a induces the expansion of CD27+ NK cells in the bone marrow. In patients with PV or ET undergoing IFN-a therapy, the frequency of CD56bright NK cells is increased and correlates with the molecular response. Depletion of NK cells abrogated the therapeutic effects of IFN-a. In vitro experiments demonstrate that NK cells preferentially killed Jak2VF mutant hematopoietic stem and progenitor cells (HSPCs) in a TNF-a dependent manner and independent of IFN-g or NKG2D. Notably, PV mice depleted of NK cells or lacking type-I interferon (IFN) receptor on NK cells showed accelerated disease progression in the absence of exogenous IFN-a. This suggests that direct sensing of basal levels of type-I IFNs by NK cells is essential for attenuating disease progression, emphasizing a critical role for NK cells in immune surveillance of MPN. These findings offer new insights into type-I IFN-mediated immune modulation in MPN and highlight the potential of NK cell activation to improve therapeutic outcomes.
- Open Access
- 19 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth
The MYB-related transcription factor and partner of profilin (MYPOP or p42POP) is a ubiquitously expressed yet understudied protein recently identified as a restriction factor of oncogenic human papillomaviruses (HPV) and proposed tumor suppressor. Here we show that in HPV-transformed cervical cancer cells, MYPOP induces alterations in cell morphology, silences viral and cellular oncogenes including E6 and MYC , and stimulates the release of the cancer-killing cytokine interleukin-24. Transcriptomic and live-cell analyses reveal a rapid G1/S-phase arrest followed by loss of viable cervical cancer cells and induction of apoptosis. Moreover, MYPOP expression is broadly diminished across multiple human cancers, and its re-expression by both DNA- and mRNA-gene transfer markedly suppresses tumor cell proliferation while sparing normal epidermal keratinocytes. Similarly, murine Mypop inhibits mouse cancer cell growth. Collectively, our findings identify MYPOP as a selective suppressor of tumor cell proliferation across species in vitro and point to its potential relevance for future therapeutic investigation.
- 19 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessThe MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth
The MYB-related transcription factor and partner of profilin (MYPOP or p42POP) is a ubiquitously expressed yet understudied protein recently identified as a restriction factor of oncogenic human papillomaviruses (HPV) and proposed tumor suppressor. Here we show that in HPV-transformed cervical cancer cells, MYPOP induces alterations in cell morphology, silences viral and cellular oncogenes including E6 and MYC , and stimulates the release of the cancer-killing cytokine interleukin-24. Transcriptomic and live-cell analyses reveal a rapid G1/S-phase arrest followed by loss of viable cervical cancer cells and induction of apoptosis. Moreover, MYPOP expression is broadly diminished across multiple human cancers, and its re-expression by both DNA- and mRNA-gene transfer markedly suppresses tumor cell proliferation while sparing normal epidermal keratinocytes. Similarly, murine Mypop inhibits mouse cancer cell growth. Collectively, our findings identify MYPOP as a selective suppressor of tumor cell proliferation across species in vitro and point to its potential relevance for future therapeutic investigation.
- Open Access
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments
- Open Access
- 14 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Solid tumors exploit proton-sensing GPR65 for orchestration of an immunosuppressive tumor microenvironment
- 14 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessSolid tumors exploit proton-sensing GPR65 for orchestration of an immunosuppressive tumor microenvironment
- 18 March 2026
- Published by American Society of Hematology in Blood
Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML
The lysine acetyltransferase (KAT) activity of p300/CREBBP has traditionally been linked to transcriptional activation. This has been attributed largely to acetylation of histone residues such as H3K27ac, a defining hallmark of active regulatory elements. Here we show that, in acute myeloid leukemia (AML), inhibition of p300/CREBBP catalysis can paradoxically increase transcription. We combined time-resolved dynamics of nascent and total transcription with chromatin binding dynamics of p300/CREBBP and their associated TFs/co-regulators (inferred from chromatin pull-down proteomics, acetyl-proteomics and motif enrichment) to uncover mechanisms of transcriptional rewiring after p300/CREBBP catalytic inhibition. In parallel, we dissected the functional contribution of individual p300/CREBBP acetyl-interactome members to KAT inhibition using genome-wide CRISPR-Cas9 dropout and focused Perturb-seq screens. Together, these approaches revealed that KAT inhibition paradoxically retains p300/CREBBP and promotes cooperative TF assembly and increased H3K27 acetylation at a subset of regulatory elements. The effect was most pronounced at IRF motif-enriched loci, including interferon-stimulated genes (ISGs), where KAT inhibition triggered p300/CREBBP accumulation and enhanced combinatorial TF binding, enabling recruitment of the ISG activator STAT1. Consequently, ISG loci were converted into transcriptionally active states that induced cell-cycle arrest, differentiation and apoptosis. Therapeutically, combining KAT inhibition with interferon-alpha augmented ISG expression, synergistically drove AML cell death in vitro and significantly extended survival in both AML xenografts and murine models. These findings refine our understanding of p300/CREBBP KAT activity, demonstrating that cooperative TF assembly can reconfigure p300/CREBBP-containing complexes under catalytic inhibition to induce transcription, with translational implications for reprogramming interferon-driven programs through catalytic inhibition in AML and beyond.
- 18 March 2026
- Published by American Society of Hematology in Blood
Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML
The lysine acetyltransferase (KAT) activity of p300/CREBBP has traditionally been linked to transcriptional activation. This has been attributed largely to acetylation of histone residues such as H3K27ac, a defining hallmark of active regulatory elements. Here we show that, in acute myeloid leukemia (AML), inhibition of p300/CREBBP catalysis can paradoxically increase transcription. We combined time-resolved dynamics of nascent and total transcription with chromatin binding dynamics of p300/CREBBP and their associated TFs/co-regulators (inferred from chromatin pull-down proteomics, acetyl-proteomics and motif enrichment) to uncover mechanisms of transcriptional rewiring after p300/CREBBP catalytic inhibition. In parallel, we dissected the functional contribution of individual p300/CREBBP acetyl-interactome members to KAT inhibition using genome-wide CRISPR-Cas9 dropout and focused Perturb-seq screens. Together, these approaches revealed that KAT inhibition paradoxically retains p300/CREBBP and promotes cooperative TF assembly and increased H3K27 acetylation at a subset of regulatory elements. The effect was most pronounced at IRF motif-enriched loci, including interferon-stimulated genes (ISGs), where KAT inhibition triggered p300/CREBBP accumulation and enhanced combinatorial TF binding, enabling recruitment of the ISG activator STAT1. Consequently, ISG loci were converted into transcriptionally active states that induced cell-cycle arrest, differentiation and apoptosis. Therapeutically, combining KAT inhibition with interferon-alpha augmented ISG expression, synergistically drove AML cell death in vitro and significantly extended survival in both AML xenografts and murine models. These findings refine our understanding of p300/CREBBP KAT activity, demonstrating that cooperative TF assembly can reconfigure p300/CREBBP-containing complexes under catalytic inhibition to induce transcription, with translational implications for reprogramming interferon-driven programs through catalytic inhibition in AML and beyond.
- 27 February 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (4)
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation
NIK (Map3k14) is a central regulator of noncanonical NF-κB signaling and immune homeostasis. Mutations in this kinase are linked to autoimmune disorders, including multiple sclerosis (MS). Both germline and T cell–specific deletion of NIK had been demonstrated previously to be associated with resistance to developing experimental autoimmune encephalomyelitis (EAE), an animal model for MS. In this study, we show that NIK expression by circulating myeloid cells is crucial for EAE development. Mechanistically, we found starkly reduced priming of neuroantigen-specific T cells in the absence of NIK in CX3CR1+ cells. This reduction was associated with dysregulated expression of genes involved in antigen presentation and cell migration, as well as decreased IL-23 production. Notably, T cells primed by NIK-deficient myeloid cells regained their ability to induce EAE when incubated with IL-23 before being transferred into RagKO mice. Our data underline the crucial role of NIK in enabling myeloid cells to function effectively as antigen-presenting cells.
- 27 February 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (4)
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation
NIK (Map3k14) is a central regulator of noncanonical NF-κB signaling and immune homeostasis. Mutations in this kinase are linked to autoimmune disorders, including multiple sclerosis (MS). Both germline and T cell–specific deletion of NIK had been demonstrated previously to be associated with resistance to developing experimental autoimmune encephalomyelitis (EAE), an animal model for MS. In this study, we show that NIK expression by circulating myeloid cells is crucial for EAE development. Mechanistically, we found starkly reduced priming of neuroantigen-specific T cells in the absence of NIK in CX3CR1+ cells. This reduction was associated with dysregulated expression of genes involved in antigen presentation and cell migration, as well as decreased IL-23 production. Notably, T cells primed by NIK-deficient myeloid cells regained their ability to induce EAE when incubated with IL-23 before being transferred into RagKO mice. Our data underline the crucial role of NIK in enabling myeloid cells to function effectively as antigen-presenting cells.
- Open Access
- 24 February 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (4) , 383-399
B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8+ T-cell response
Natural killer and CD8 + T cells are critical in the elimination of blood-borne viruses such as cytomegalovirus (CMV); however, the role of B cells in this process is less clear. Here, using a murine CMV (MCMV) infection model, we demonstrated that B-cell-deficient mice mounted a weaker primary virus-specific CD8 + T-cell response than their wild-type counterparts did, which was associated with increased viral transcription. Notably, we found that the contribution of B cells to the CD8 + T-cell-mediated antiviral response was not associated with their ability to generate antibodies but with their ability to sustain Langerin + type 1 conventional dendritic cells (cDC1s), a dendritic cell (DC) subset known for being involved in viral and bacterial clearance in the marginal zone of the spleen. Furthermore, we found that the presence of Langerin + cDC1s is dependent on B cells expressing lymphotoxin (LTβ) to maintain CD169 + marginal metallophilic macrophages (MMMs). We further discovered, via ligand‒receptor interaction analyses, that the communication between MMMs and Langerin + cDC1s was mediated via the VCAM1–ITGA4/ITGB1 interaction. Thus, our data reveal that B cells regulate the development of MMMs in the spleen via LTβ expression and consequently sustain Langerin + cDC1 homeostasis for effective initiation of an antiviral CD8 + T-cell response. Overall, our study offers a new perspective on how B cells maintain the homeostasis of antigen-presenting cells in the splenic marginal zone and thus indirectly affect the virus-specific CD8 + T-cell response, which could be extended to other infectious and autoimmune diseases as well as tumors.
- 24 February 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (4) , 383-399
Open AccessB cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8+ T-cell response
Natural killer and CD8 + T cells are critical in the elimination of blood-borne viruses such as cytomegalovirus (CMV); however, the role of B cells in this process is less clear. Here, using a murine CMV (MCMV) infection model, we demonstrated that B-cell-deficient mice mounted a weaker primary virus-specific CD8 + T-cell response than their wild-type counterparts did, which was associated with increased viral transcription. Notably, we found that the contribution of B cells to the CD8 + T-cell-mediated antiviral response was not associated with their ability to generate antibodies but with their ability to sustain Langerin + type 1 conventional dendritic cells (cDC1s), a dendritic cell (DC) subset known for being involved in viral and bacterial clearance in the marginal zone of the spleen. Furthermore, we found that the presence of Langerin + cDC1s is dependent on B cells expressing lymphotoxin (LTβ) to maintain CD169 + marginal metallophilic macrophages (MMMs). We further discovered, via ligand‒receptor interaction analyses, that the communication between MMMs and Langerin + cDC1s was mediated via the VCAM1–ITGA4/ITGB1 interaction. Thus, our data reveal that B cells regulate the development of MMMs in the spleen via LTβ expression and consequently sustain Langerin + cDC1 homeostasis for effective initiation of an antiviral CD8 + T-cell response. Overall, our study offers a new perspective on how B cells maintain the homeostasis of antigen-presenting cells in the splenic marginal zone and thus indirectly affect the virus-specific CD8 + T-cell response, which could be extended to other infectious and autoimmune diseases as well as tumors.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model
Supplementary Table S1-3 and Figures S1-6
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model
Supplementary Table S1-3 and Figures S1-6